An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study

Table 2 Patient demographics and exposure

Patient number	Amyloid type	Site(s) of involvement*	Age^† (years)	Gender	Time from diagnosis to baseline^‡ (months)	Time from baseline to study termination date or death (months)	Assessments during follow-up study, n	Doses received	Time from final dose to final follow-up (months)
001	AA	Kidney	60	Female	27	63.9	6	1	63.9
012	AA	Kidney	62	Female	27	54.7	4	1	54.7
102	AFib	Kidney	58	Male	53	43.9	7	2	43.9
104	AFib	Kidney	68	Male	55	46.0	16	3	40.7
105	AFib	Kidney	60	Male	38	47.1	12	3	43.7
106	AFib	Kidney	62	Female	158	43.7	3	2	43.7
107	AL	Liver	65	Female	126	46.9	5	3	41.4
108	AL	Liver and kidney	61	Male	12	58.0	9	2	47.1
109	ApoA1	Liver	46	Female	52	56.3	12	3	41.6
110	AL	Liver	60	Male	24	55.9	8	3	43.4
111	AL	Liver	63	Female	90	30.2^§	5	3	18.9
113	AL	Liver and kidney	49	Female	72	51.7	4	2	46.0
114	AL	Liver	53	Male	21	51.3	8	3	42.7
115	AL	Liver	67	Female	29	50.4	6	2	38.4
116	AL	Liver	44	Female	19	49.9	8	3	41.1
117	AFib	Kidney	69	Male	6	42.9	11	1	42.9
118	AL	Cardiac	50	Male	48	41.6	9	3	36.3
119	AL	Liver	69	Female	53	41.6	5	1	41.6
120	AL	Cardiac and kidney	50	Male	86	10.8^§	2	1	10.8
121	AL	Cardiac and kidney	47	Female	23	41.2	6	3	35.8
123	ATTR (hereditary)	Cardiac	66	Male	18	33.5^§	6	1	33.5
124	ATTR (wild-type)	Cardiac	68	Male	18	35.0	6	1	34.9
125	ATTR (wild-type)	Cardiac	66	Male	5	34.7	7	1	34.7

*Other organs may also have been affected, for example, spleen, bone marrow, adrenals
^†At entry into FIHS
^‡The baseline date was defined as the date of first pharmacologically active administration of dezamizumab (i.e. ≥ 200 mg) in the FIHS. For the one subject who received a non-pharmacologically active dose (i.e. < 200 mg), their baseline date was defined as the date of first administration of a non-pharmacologically active dose of dezamizumab
^§Patient died
AA, serum amyloid A; AFib, fibrinogen A alpha-chain; AL, immunoglobulin light chain; ApoA1, apolipoprotein A-I; ATTR, transthyretin

ISSN: 1750-1172